Mineralys Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 31, 2026, an affiliate of the Company, Catalys Pacific Fund, LP, entered into a Rule 10b5-1 trading plan. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Brian Taylor Slingsby, M.D., Ph.D., M.P.H., one of our directors, is the managing director of Catalys Pacific, LLC, the general partner of Catalys Pacific Fund GP, LP, and has voting and investment power over the shares held by Catalys Pacific Fund, LP. The material terms of this Rule 10b5-1 trading arrangement are described below:
| Name and Title | Action Taken | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Number of Securities |
|---|---|---|---|---|---|
| Catalys Pacific Fund, LP | Adoption January 9, 2026 | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | May 9, 2026 to March 31, 2027 | 2,000,000 |
Except as set forth above, during the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted orterminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
Item 6. Exhibits
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.